Heidelberg Pharma Advances Novel ATAC Technology Platform with Multiple Cancer Candidates in Clinical Development
Key Insights
Heidelberg Pharma (search) has pioneered the use of Amanitin (search) from the green death cap mushroom in cancer therapy, developing the novel ATAC antibody-drug conjugate technology platform.
The company's lead candidate HDP-101 for multiple myeloma (search) has received FDA Orphan Drug and Fast Track Designations, while HDP-102 is advancing in Non-Hodgkin Lymphoma (search) trials.
Two additional ATAC candidates, HDP-103 for metastatic castration-resistant prostate cancer (search) and HDP-104 for gastrointestinal tumors, have completed preclinical development.
Heidelberg Pharma (search) has established itself as the first company to harness Amanitin (search) from the green death cap mushroom for cancer therapy, developing a novel antibody-drug conjugate platform that represents a new therapeutic modality in oncology. The German biotechnology company's innovative ATAC (Amanitin-based ADC) technology has generated multiple clinical-stage candidates targeting various cancer indications.
Lead Candidate Shows Promise in Multiple Myeloma
The company's most advanced program, HDP-101 (INN: pamlectabart tismanitin (search)), is a BCMA (search)-targeting ATAC currently in clinical development for multiple myeloma (search). This lead candidate has achieved significant regulatory recognition, receiving both Orphan Drug Designation and Fast Track Designation from the FDA, highlighting its potential to address unmet medical needs in this hematologic malignancy.
Expanding Pipeline Across Multiple Cancer Types
Heidelberg Pharma (search)'s second ATAC candidate, HDP-102, is progressing through clinical development for Non-Hodgkin Lymphoma (search), demonstrating the platform's versatility across different hematologic cancers. The company has also advanced two additional candidates through preclinical development: HDP-103, designed to target metastatic castration-resistant prostate cancer (search), and HDP-104, which focuses on gastrointestinal tumors including colorectal cancer (search).
Novel Mechanism of Action
The biological mechanism of action of the Amanitin (search) toxin represents a distinct therapeutic approach in cancer treatment. This compound, derived from the green death cap mushroom, forms the foundation of Heidelberg Pharma (search)'s proprietary ATAC technology platform, which combines the targeting specificity of antibodies with the potent cytotoxic effects of the Amanitin payload.
Strategic Positioning and Partnerships
Based in Ladenburg, Germany, Heidelberg Pharma (search) is listed on the Frankfurt Stock Exchange under the symbol HPHA. The company has demonstrated its ability to advance programs through clinical development, as evidenced by its previous work with TLX250-Px (search), a radiolabeled form of the antibody girentuximab that binds to the tumor-specific antigen CAIX (search) on clear cell renal cell carcinoma (search). Heidelberg Pharma developed this antibody through a completed Phase III clinical trial before licensing it to Telix Pharmaceuticals Limited (search) in 2017.
The company remains open to partnering opportunities as it continues to advance its ATAC technology platform across multiple cancer indications. With ATAC serving as a registered trademark of Heidelberg Pharma (search) Research GmbH, the company has established intellectual property protection around its innovative approach to cancer therapy.